Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erdafitinib in High-Risk NMIBC with FGFR Alterations (THOR-2)
NCT04172675Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2020
- Primary completion
- Jul 2024
- Countries
- 17
01
Overview
A Phase 2 trial of erdafitinib in Non-muscle-invasive bladder cancer (NMIBC), sponsored by Janssen Pharmaceutical. Started Feb 2020; status: completed.
02
Drugs
erdafitinib
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT04172675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04172675.